ClinicalTrials.gg
Active, not recruitingNCT04683003Updated Apr 2, 2026

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

A Phase 3 interventional study of TAK-755 in Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda. Active, not recruiting at 27 sites in 11 countries. Open to participants aged 0 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
77
Allocation
Non-randomized
Ages
0 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda — 3 open to participants now, 4 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · Takeda.

Started
2021
the only one that year
Phase 3
2 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, this one is the only one that started in 2021, is one of 2 in phase 3, and was the 5th registered.

Purpura, Thrombotic Thrombocytopenic

67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.

Browse Purpura, Thrombotic Thrombocytopenic studies →

Open to participants now

3 of the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 0 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, or all of them as a file.
02

Study summary

Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them, leading to fewer red blood cells than in normal.

TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events.

The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways:

  1. TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort).
  2. TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort).

Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will have a follow-up visit at the clinic 4 weeks later.

Read the detailed description

This is a follow-up study to the Phase 3 pivotal study (281102 [NCT03393975]) and will be comprised of two treatment cohorts (Prophylactic and On-demand) consisting of naïve and non-naïve participants who were born with TTP, with a total duration of approximately 6 years. A maximum of approximately 77 participants will be enrolled in this study (approximately 57 participants who have completed study 281102 [NCT03393975] [non-naïve participants] and at least 20 naïve participants (participants who are naïve to TAK-755). Participants from Expanded Access Programs, participants from study 281102 (NCT03393975) who had an allergic reaction to standard of care treatment, and participants who completed the Phase 1 study (281101 [NCT02216084]) but did not participate in Study 281102, will also be eligible for enrollment in this continuation study as naïve participants.

TAK-755 is given slowly through a vein (intravenous infusion). Participants in the prophylactic cohort will be able to opt for treatment in a home setting by caregiver or self-infusion subject to conditions and to local regulatory approval.

03

Conditions studied

  • Thrombotic Thrombocytopenic Purpura (TTP)

Keywords

  • Congenital Thrombotic Thrombocytopenic Purpura (TTP)
04

Who can participate

Ages eligible
0 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who have completed TAK-755 Phase 3 pivotal Study 281102 (NCT03393975) in the prophylactic cohort and who meet all of the following criteria are eligible for this study:

  • Participants or legally authorized representative has provided signed >=18 years of age and/or assent form \<18 years of age.
  • Participant 0 to 70 years of age at the time of screening of the 281102 (NCT03393975) study.
  • Participant has been diagnosed with severe congenital ADAMTS-13 deficiency.
  • Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs ( count \<100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (>) 2 × at screening (prophylactic cohort only).
  • Participants >=16 years of age must have a score >= 70% and participants \<16 years of age must have a Lansky score >=80%.
  • If female of , participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ adequate measures for the duration of the study and to undergo quarterly pregnancy testing.
  • Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered.
  • Participant is willing and able to comply with the requirements of the protocol.

All naïve participants and non-naïve on-demand cohort participants:

Naïve participants can only be enrolled in this continuation after enrollment of the adult participants in the prophylactic arm of TAK-755 Phase 3 pivotal study 281102 (NCT03393975) has been completed. Naïve pediatric participants can be enrolled after enrollment of the respective age cohort into the pivotal Phase 3 study 281102 (NCT03393975) has been completed. The following criteria also applies to participants who completed study 281101 (NCT02216084), but did not participate in 281102 (NCT03393975).

Naïve participants and participants who were enrolled into the on-demand cohort of theTAK-755 Phase 3 pivotal study 281102 (NCT03393975) who meet ALL of the following criteria are eligible for this study:

  • Participant is naïve or was enrolled into the on-demand cohort of the TAK-755 Phase 3 pivotal study 281102 (NCT03393975) for treatment of an acute TTP event but did not receive prophylactic treatment.
  • Participant or legally authorized representative has provided signed informed consent (>=18 years of age) and/or assent form (\<18 years of age).
  • Participant is 0 to 70 years of age at the time of screening.
  • Participant has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:

    • Confirmed by molecular genetic testing, documented in participant history or at screening, and
    • ADAMTS-13 activity \<10% as measured by the fluorescence resonance energy transfer (FRETS)-VWF73 assay, documented in participant history or at screening. Participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS-13 activity at screening.
  • Participants currently receiving prophylactic therapy will be screened immediately prior to their usual prophylactic infusion.
  • Participant does not display any severe TTP signs (platelet count \<100,000/microliter (mcL) and elevation of LDH >2 × ULN) at screening (prophylactic cohort only).
  • Participants >=16 years of age must have a Karnofsky score >=70% and participants \<16 years of age must have a Lansky score >=80%.
  • Participants is virus negative (HCV-) as confirmed by antibody or polymerase chain reaction testing OR HCV positive (HCV+) if their disease is chronic but stable.
  • If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
  • Sexually active males must use an accepted and effective method of contraception during treatment and until a minimum of 16 days after the last dose administered.
  • Participant is willing and able to comply with the requirements of the protocol.

Participants from an Expanded Access Program or participants in Study 281102 (NCT03393975) who had an allergic reaction to standard of care prophylactic treatment must meet all of the following criteria:

Participants from an expanded access program as well as participants who participated in Study 281102(NCT03393975) who had an allergic reaction to standard-of-care prophylactic treatment are eligible for enrollment in the continuation study if they meet ALL of the following criteria.

  • Participants or legally authorized representative has provided signed informed consent (>=18 years of age) and/or assent (\<18 years of age).
  • Participants is 0 to 70 years of age at the time of screening.
  • Participants has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:

    • Confirmed by molecular genetic testing, documented in participant history or at screening, and
    • ADAMTS-13 activity \<10% as measured by the fluorescence resonance energy transfer (FRETS)- VWF 73 assay, documented in participant history or at screening. Participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS 13 activity at screening.
  • Participant does not display any severe TTP signs (platelet count \<100,000/mcL and elevation of LDH >2 × ULN) at screening (prophylactic cohort only).
  • Participants >=16 years of age must have a Karnofsky score >=70% and participants \<16 years of age must have a Lansky score >=80%.
  • If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ highly effective birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
  • Sexually active males must use an accepted and effective method of contraception during treatment and until a minimum of 16 days after the last dose administered.
  • Participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

Participants who have completed TAK-755 Phase 3 pivotal study (281102) (NCT03393975) and naïve participants and non-naïve on-demand cohort participants and participants from an Expanded Access Program or participants in Study 281102 (NCT03393975) who had an allergic reaction to standard-of-care prophylactic treatment. The following criteria also applies to participants who completed study 281101 (NCT02216084), but did not participate in 281102 (NCT03393975).

  • Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including immune-mediated TTP.
  • Known life-threatening reaction, including anaphylaxis, to the parent molecule ADAMTS-13, hamster protein, or other constituents of TAK-755.
  • Participant has a presence of a functional ADAMTS-13 inhibitor at screening.
  • Participant has a medical history of a genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are -positive with an absolute cluster of differentiation 4 (CD4) count \< 200/ cubic millimeter (mm\^3) or who are receiving chronic drugs.
  • Participant has a history of significant neurological events, such as major stroke, indicating that a relapse might have severe consequences, as judged by the investigator.
  • Participant has been diagnosed with severe cardiovascular disease ( classes 3 to 4).
  • Participant with end stage renal disease requiring chronic dialysis.
  • Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following:

    • Serum >= 2 ×
    • Severe hypoalbuminemia \<24 gram per liter (g/L)
    • Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal varices).
  • In the opinion of the investigator, the participant has another concomitant disease that may pose additional risks for the participant.
  • Participant has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of in conjunction with administration of fresh frozen plasma to prevent allergic reactions is permitted.
  • Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylactic cohort only).
  • Participant is receiving or anticipates receiving another drug and/or interventional drug within 30 days before enrollment.
  • Participant has a history of drug and/or alcohol abuse within the last 2 years.
  • Participant has a progressive fatal disease and/or of \<= 3 months.
  • Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.
  • Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude.
  • Participant is a family member or employee of the sponsor or investigator.
  • If female, participant is pregnant or lactating at the time of enrollment.
  • In the UK only: Participants who have not previously received a dose of TAK-755.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (estimated)

Study arms

  • Experimental
    Prophylactic Cohort: TAK-755

    All participants will receive prophylactic treatment with 40 IU/kg TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study. Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with 40 IU/kg TAK-755 by IV infusion once every week or once every other week for the duration of the study.

    Biological: TAK-755

  • Experimental
    On-Demand Cohort: TAK-755

    Participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved. Participants will receive 40 IU/kg TAK-755 on the first day, followed by 20 IU/kg on Day 2, and then 15 IU/kg daily until 2 days after the acute TTP event has resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study.

    Biological: TAK-755

Interventions

  • BiologicalTAK-755

    TAK-755 IV infusion

    Also known as: rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930

06

What researchers measure

Primary outcomes

  1. Incidence of Related Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAE: any adverse event emerging or manifesting at or after the initiation of treatment with TAK-755 or any existing adverse event that worsens in either intensity or frequency following exposure to TAK-755. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event.

    Time frame: Throughout the study period of approximately 6 years

Secondary outcomes

  1. Number of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events in Participants with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Undergoing Prophylactic Treatment with TAK-755

    The number of acute TTP Events in participants with cTTP receiving prophylactic treatment with TAK-755 (rADAMTS13) will be assessed.

    Time frame: Up to approximately 3 years

  2. Incidence Rate of Acute TTP Events in Participants with cTTP Undergoing Prophylactic Treatment with TAK-755

    Annualized acute TTP event incidence rate is calculated as the number of acute TTP events while receiving prophylactic treatment with TAK-755 (rADAMTS13) divided by the duration of the observation period in years. Annualized acute TTP event rate while participants are receiving prophylactic treatment with TAK-755 will be assessed.

    Time frame: Up to approximately 3 years

  3. Number of Acute TTP Events Resolved After Treatment with TAK-755 while Enrolled in the Study

    Acute TTP events are considered resolved when: Platelet count is \>=150,000/ μL or platelet count is within 25% of baseline and elevation of lactate dehydrogenase (LDH) \<= 1.5 x baseline or \<= 1.5 x upper limit of normal (ULN).

    Time frame: Throughout the study period of approximately 6 years

  4. Proportion of Acute TTP Events Resolved After Treatment with TAK-755 while Enrolled in the Study

    Proportion of acute TTP events that have resolved after treatment with TAK-755 (rADAMTS13) while enrolled in the study will be assessed. Acute TTP events are considered resolved when: Platelet count is \>=150,000/ μL or platelet count is within 25% of baseline and elevation of LDH \<= 1.5 x baseline or \<= 1.5 x ULN.

    Time frame: Throughout the study period of approximately 6 years

  5. Incidence of Acute TTP Events while Participants are on Their Final Dose and Dosing Regimen

    Incidence of annualized acute TTP events while participants are on their final dose and dosing regimen will be assessed.

    Time frame: Throughout the study period of approximately 6 years

  6. Time to Resolution of Acute TTP Events Following Treatment with IP

    Time to resolution of acute TTP event is defined as the time from initial treatment of the event to resolution of the acute TTP event. Acute TTP events are considered resolved when: Platelet count is \>=150,000/ μL or platelet count is within 25% of baseline and elevation of LDH \<= 1.5 x baseline or \<= 1.5 x ULN.

    Time frame: Throughout the study period of approximately 6 years

  7. Total Quantity of TAK-755 Administered During the Treatment of Acute TTP Events

    Total quantity of TAK-755 administered during the treatment of acute TTP events will be assessed. Acute events typically require 3-4 days of intensified treatment.

    Time frame: Throughout the study period of approximately 6 years

  8. Incidence of Supplemental Doses Prompted by Subacute TTP Events

    Incidence of supplemental doses prompted by subacute TTP events in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  9. Incidence of Dose Modifications Not Prompted by an Acute TTP Event

    Incidence of dose modifications not prompted by an acute TTP event in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  10. Incidence of Thrombocytopenia

    Thrombocytopenia is defined as a drop in platelet count \>=25 percent (%) of baseline or a platelet count less than (\<) 150,000/mcL. Incidence of thrombocytopenia in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  11. Incidence of Microangiopathic Hemolytic Anemia

    Microangiopathic hemolytic anemia is defined as an elevation of LDH greater than (\>) 1.5xbaseline or LDH \> 1.5xULN. Incidence of microangiopathic hemolytic anemia in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  12. Incidence of Neurological Symptoms

    Neurological symptoms include headache, confusion, dysphonia, dysarthria, focal or general motor symptoms including seizures. Incidence of neurological symptoms in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  13. Incidence of Renal Dysfunction

    Renal dysfunction is defined as an increase in serum creatinine \>1.5xbaseline. Incidence of renal dysfunction in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  14. incidence of Abdominal Pain

    Incidence of abdominal pain in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  15. Incidence of TTP Manifestations for Participants Receiving TAK-755 as a Prophylactic Treatment

    TTP manifestations are defined as a composite of thrombocytopenia, microangiopathic hemolytic anemia, and TTP-related signs/symptoms including but not limited to (renal signs, neurologic symptoms, fever, fatigue/lethargy and abdominal pain). Incidence of TTP manifestations in the prophylactic cohort will be assessed.

    Time frame: Up to approximately 3 years

  16. Incidence of TTP Manifestations While Receiving the Final Prophylactic Treatment Regimen with TAK-755 in the Home Setting

    TTP manifestations are defined as a composite of thrombocytopenia, microangiopathic hemolytic anemia, and TTP-related signs/symptoms including but not limited to (renal signs, neurologic symptoms, fever, fatigue/lethargy and abdominal pain). Incidence of TTP manifestations in the prophylactic cohort in the home setting will be assessed.

    Time frame: Up to approximately 3 years

  17. Incidence of Acute TTP Events in Participants Receiving TAK-755 Prophylactically in the Home Setting

    Incidence of acute TTP events in participants receiving TAK-755 prophylactically in the home setting will be assessed.

    Time frame: Up to approximately 3 years

  18. Incidence of all AEs and SAEs (Including Unrelated)

    AE: any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this IP or medicinal product. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event.

    Time frame: Throughout the study period of approximately 6 years

  19. Proportion of Participants with anti-ADAMTS13 Binding Antibodies and Neutralizing Antibodies Following ADAMTS13 Administration

    Proportion of participants with anti-ADAMTS13 binding antibodies and neutralizing antibodies following ADAMTS13 administration will be assessed.

    Time frame: Throughout the study period of approximately 6 years

  20. Number of Participants Experiencing TAK-755 Related AEs and SAEs After Receiving TAK-755 in the Home Setting

    AE: Any untoward medical occurrence in a participant administered IP that does not necessarily have a causal relationship with the treatment. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event.

    Time frame: Throughout the study period of approximately 6 years

  21. Number of Participants with AEs and SAEs After Receiving TAK-755 in the Home Setting

    AE: Any untoward medical occurrence in a participant administered IP that does not necessarily have a causal relationship with the treatment. SAE: Signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event.

    Time frame: Throughout the study period of approximately 6 years

  22. Health Related Quality of Life (HRQoL): cTTP-Specific Patient reported outcomes (PROs)

    The cTTP specific patient-reported outcomes (PRO) instrument consists of 26 questions designed to assess the participants experience of fatigue, joint, muscle, abdominal and chest pain in the previous 24 hours, neurologic manifestations, bruising, feelings of depression and mood alterations, and activity limitation in the past 7 days, and participants attitudes, experienced side effects, work/school absences and travel impact associated with treatment received for TTP during the previous 2 weeks. The cTTP PRO assessment is focused on measuring the symptoms and impacts of the disease. The scores range from 0 to 152. Higher scores indicate a better quality of life.

    Time frame: Throughout the study period of approximately 6 years

  23. HRQoL: 36-Item Short Form Health Survey (SF-36)

    The SF-36 is a generic quality-of-life instrument that has been widely used to assess HRQoL of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQoL.

    Time frame: Throughout the study period of approximately 6 years

  24. HRQoL: Abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)

    TSQM is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

    Time frame: Throughout the study period of approximately 6 years

  25. HRQoL: EuroQol 5 Dimensions Questionnaire 3-Level (EQ-5D-3L)

    EQ-5D-3L health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.

    Time frame: Throughout the study period of approximately 6 years

  26. HRQoL: EQ-5D-youth (EQ-5D-Y)

    EQ-5D-Y health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.

    Time frame: Throughout the study period of approximately 6 years

  27. HRQoL: Pediatric Quality of Life Inventory (Peds QL)

    The Peds QL is a generic health related quality of life instrument designed specifically for a pediatric population and captures following domains: physical functioning, emotional functioning, social functioning, school functioning, psychosocial summary, physical health and total score. The Peds-QL total score consist of all 23 items of all domains. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better quality of life.

    Time frame: Throughout the study period of approximately 6 years

  28. HRQoL: Infusion Experience Satisfaction Assessment Questionnaire

    Infusion experience satisfaction assessment questionnaire will assess participant satisfaction on various aspects of the infusion experience (i.e., Convenience, impact on daily life, comfort in the treatment environment, time invested to receive infusion, concerns on handling potential complications, interaction with members of health care team and with other participants). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction.

    Time frame: Throughout the study period of approximately 6 years

  29. Resource Utilization: Length of Hospital Stay for Acute TTP Events

    Number of days of participants stay in hospital for acute TTP events will be assessed.

    Time frame: Throughout the study period of approximately 6 years

  30. Resource Utilization: Number of Hospitalizations for Acute TTP Events

    Number of hospitalizations for acute TTP events will be assessed.

    Time frame: Throughout the study period of approximately 6 years

  31. Resource Utilization: Number of Participants with Healthcare Resource Utilization During Prophylaxis

    Health care resource utilization including days missed from school/work due to TTP-related illness will be assessed for the prophylactic cohort.

    Time frame: Up to approximately 3 years

  32. Resource Utilization: Number of Participants with Days Missed From School or Work due to TTP-Related Illness

    Number of participants with days missed from school or work due to TTP-related illness will be assessed.

    Time frame: Throughout the study period of approximately 6 years

  33. Assessment of Trough and Postdose ADAMTS13 Activity: Antigen Levels (Activity:Ag)

    Trough and postdose ADAMTS13 activity and antigen levels from participants in prophylactic and on-demand cohorts during the study and during acute and subacute TTP events will be assessed.

    Time frame: At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years)

  34. Assessment of Von Willebrand Factor: Antigen (VWF:Ag)

    VWF:Ag is a measure of total VWF protein and will be assessed using a sandwich enzyme-linked immunosorbent assay (ELISA) employing polyclonal anti-human-VWF antibodies. Assessments of VWF:Ag at baseline and following infusion of the TAK-755 treatment during the initial PK assessment in prophylactic and on-demand cohorts and during acute TTP events will be reported.

    Time frame: At trough pre-infusion and 65 minutes post-infusion at interval study visits every 12 weeks (up to 6 years)

  35. Assessment of Von Willebrand Factor: Ristocetin Cofactor Activity (VWF:RCo)

    VWF:RCo will provide a measure of the ability of VWF to bind platelet glycoprotein Ib. Stabilized platelets are agglutinated in the presence of VWF and the antibiotic Ristocetin. Assessments of VWF:RCo during the study from participants in both the on-demand cohorts and during acute events will be reported.

    Time frame: At trough pre-infusion and 65 minutes post-infusion at interval study visits every 12 weeks (up to 6 years)

  36. Assessment of VWF:Ag in Relation to ADAMTS13 Activity Levels

    VWF:Ag is a measure of total VWF protein and will be assessed using a sandwich ELISA employing polyclonal anti-human-VWF antibodies. Longitudinal relationship of observed ADAMTS13 activity levels and VWF:Ag following infusion of the TAK-755 treatment during the initial PK assessment will be assessed (for TAK-755 naïve participants only).

    Time frame: At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years)

  37. Assessment of VWF:RCo in Relation to ADAMTS13 Activity Levels

    VWF:RCo will provide a measure of the ability of VWF to bind platelet glycoprotein Ib. Stabilized platelets are agglutinated in the presence of VWF and the antibiotic Ristocetin. Longitudinal relationship of observed ADAMTS13 activity levels and VWF:RCo following infusion of the TAK-755 treatment during the initial PK assessment will be assessed (for TAK-755 naïve participants only).

    Time frame: At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years)

  38. Number of Participants with Acute and Subacute Events in Relation with ADAMTS13 Activity Levels

    Longitudinal relationship of ADAMTS13 activity levels and participants with acute and subacute TTP events will be assessed.

    Time frame: At trough (for acute events) and within 72 hours pre-infusion and 65 minutes post-infusion (for both acute and subacute) at interval study visits every 12 weeks (up to 6 years)

07

Study locations

27 sites
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Mar 2027, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2020
First posted
Dec 24, 2020
StartActual
Apr 14, 2021
Primary completionEst.
Mar 16, 2027
CompletionEst.
Mar 16, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04683003
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc., Shire
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Apr 14, 2021
Primary completion
Mar 16, 2027 (estimated)
Completion
Mar 16, 2027 (estimated)
Last update
Apr 2, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apadamtase alfa

Start the discussion